UPDATE: Teva's (TEVA) '302 Capaxone Patent Invalidated by U.S. Patent Office

September 1, 2016 2:42 PM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - September 1, 2016 2:51 PM EDT)

Teva Pharma (NYSE: TEVA) lost a third court ruling against Mylan (NASDAQ: MYL) related to Teva's drug Copaxone. Today's decision by the U.S. Patent and Trademark Office stated that claims 1-12 of the ’302 patent are held unpatentable. Previously two other patents were invalidated.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Litigation

Add Your Comment